CSR Report 2010 2 President, Mitsubishi Heavy Industries, Ltd
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Daiichi Sankyo Company, Limited
[Translation] CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS For the Fiscal Period Ended March 31, 2011 Daiichi Sankyo Company, Limited - 1 - [Translation] (Securities Identification Code 4568) May 31, 2011 To Shareholders, Daiichi Sankyo Company, Limited Joji Nakayama, Representative Director and President & CEO 5-1, Nihonbashi Honcho 3-chome, Chuo-ku, Tokyo, Japan CONVOCATION NOTICE OF THE 6TH ORDINARY GENERAL MEETING OF SHAREHOLDERS We wish to extend our deepest sympathy to all those who have suffered hardship from the Great East Japan Earthquake that occurred in March 2011. Daiichi Sankyo Company, Limited (“the Company”) respectfully requests your attendance at the 6th Ordinary General Meeting of Shareholders (“the Meeting”), which will be held as detailed below. If you will not be able to attend the Meeting, you may exercise your voting rights through either of the methods described below, in which case we ask that you please exercise your voting rights by 17:30 (within our business hours), Friday, June 24, 2011 (Japan Time), after examining the attached reference documents. [Exercise of Voting Rights by Mail] Please indicate your approval or disapproval for the proposals on the enclosed voting form and return the form to the Company. Please note that the form must be received by the Company no later than the above-mentioned deadline. [Exercise of Voting Rights on the Internet etc.] After examining “Information on Exercise of Voting Rights, etc.” on pages 57 and 58, please vote on the Internet at the dedicated voting website (http://www.evote.jp/) no later than the above-mentioned deadline. The Company is participating in the platform for electronic exercise of voting rights for institutional investors operated by ICJ Inc. -
CSR Report 2009
Locations Head Office 16-5, Konan 2-chome, Minato-ku, Tokyo Postal Code: 108-8215 Phone: 81-3-6716-3111 (main number) Fax: 81-3-6716-5800 Headquarters and Divisions General Machinery & Special Vehicle Headquarters 3000, Tana, Sagamihara, Kanagawa Postal Code: 229-1193 Phone: 81-42-761-1101 (General Affairs Dept.) Fax: 81-42-763-0800 Air-Conditioning & Refrigeration Systems Headquarters 3-1, Asahi, Nishi-biwajima-cho, Kiyosu, Aichi Postal Code: 452-8561 Phone: 81-52-503-9200 (General Affairs Dept.) Fax: 81-52-503-3533 Paper & Printing Machinery Division 1-1-1, Itozaki-Minami, Mihara, Hiroshima Postal Code: 729-0393 Phone: 81-848-67-2054 (General Affairs & Labor Section) Fax: 81-848-63-4463 Machine Tool Division 130, Roku-jizo, Ritto, Shiga Postal Code: 520-3080 Phone: 81-77-553-3300 (General Affairs Dept.) Fax: 81-77-552-3745 Works Nagasaki Shipyard & Machinery Works 1-1, Akunoura-machi, Nagasaki Postal Code: 850-8610 Phone: 81-95-828-4121 (General Affairs Dept.) Fax: 81-95-828-4034 Kobe Shipyard & Machinery Works 1-1-1, Wadasaki-cho, Hyogo-ku, Kobe Postal Code: 652-8585 Phone: 81-78-672-2220 (General Affairs Dept.) Fax: 81-78-672-2245 Address all inquiries about this report to: Shimonoseki Shipyard & Machinery Works 6-16-1, Hikoshima Enoura-cho, Shimonoseki Postal Code: 750-8505 Mitsubishi Heavy Industries, Ltd. Phone: 81-83-266-5978 (General Affairs & Labor Section) Corporate Social Responsibility Department Fax: 81-83-266-8274 CSR Report 16-5, Konan 2-chome, Minato-ku, Tokyo, Japan Yokohama Machinery Works 1-8-1, Sachiura, Kanazawa-ku, -
Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone?
IRLE IRLE WORKING PAPER #188-09 September 2009 Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone? James R. Lincoln, Masahiro Shimotani Cite as: James R. Lincoln, Masahiro Shimotani. (2009). “Whither the Keiretsu, Japan's Business Networks? How Were They Structured? What Did They Do? Why Are They Gone?” IRLE Working Paper No. 188-09. http://irle.berkeley.edu/workingpapers/188-09.pdf irle.berkeley.edu/workingpapers Institute for Research on Labor and Employment Institute for Research on Labor and Employment Working Paper Series (University of California, Berkeley) Year Paper iirwps-- Whither the Keiretsu, Japan’s Business Networks? How Were They Structured? What Did They Do? Why Are They Gone? James R. Lincoln Masahiro Shimotani University of California, Berkeley Fukui Prefectural University This paper is posted at the eScholarship Repository, University of California. http://repositories.cdlib.org/iir/iirwps/iirwps-188-09 Copyright c 2009 by the authors. WHITHER THE KEIRETSU, JAPAN’S BUSINESS NETWORKS? How were they structured? What did they do? Why are they gone? James R. Lincoln Walter A. Haas School of Business University of California, Berkeley Berkeley, CA 94720 USA ([email protected]) Masahiro Shimotani Faculty of Economics Fukui Prefectural University Fukui City, Japan ([email protected]) 1 INTRODUCTION The title of this volume and the papers that fill it concern business “groups,” a term suggesting an identifiable collection of actors (here, firms) within a clear-cut boundary. The Japanese keiretsu have been described in similar terms, yet compared to business groups in other countries the postwar keiretsu warrant the “group” label least. -
April 18, 2007 Press Release Ajinomoto Co., Inc. Eisai Co., Ltd
April 18, 2007 Press Release Ajinomoto Co., Inc. Eisai Co., Ltd. Takeda Pharmaceutical Company Limited A ONCE-WEEKLY FORMULATION OF RISEDRONATE SODIUM HYDRATE, AN ANTIOSTEOPOROTIC AGENT, WAS APPROVED. Ajinomoto Co., Inc. (“Ajinomoto”, President and CEO: Norio Yamaguchi, Headquarters: Tokyo) and Takeda Pharmaceutical Company Limited (“Takeda”, President: Yasuchika Hasegawa, Headquarters: Osaka) are pleased to announce that the Ministry of Health, Labour and Welfare approved today “ActonelⓇ 17.5 mg tablets” and “BenetⓇ 17.5 mg tablets”, a once-weekly formulation of risedronate sodium hydrate (generic name) for the treatment of osteoporosis. Both Ajinomoto and Takeda own the drug manufacturing approval of above products while Eisai Co., Ltd. (“Eisai”, President and CEO: Haruo Naito, Headquarters: Tokyo) will distribute “ActonelⓇ 17.5 mg tablets” supplied by Ajinomoto, and Takeda will distribute “BenetⓇ 17.5 mg tablets” respectively. Risedronate sodium hydrate is a bisphosphonate antiosteoporotic agent, which was originally synthesized by Norwich Eaton Pharmaceuticals, Inc. in the United States (then a subsidiary of The Procter & Gamble Company and now Procter & Gamble Pharmaceuticals, Inc.). This agent has two distinctive features from other antiosteoporotics: In the additional analysis of large clinical trials, vertebral and non-vertebral bone fractures suppressing effects of this agent showed statistically significant difference as compared to placebo as early as 6 months after starting administration. In large clinical trials with the primary endpoint of the reduction of frequency of hip fractures, this agent showed statistically significant difference as compared to placebo. The once-weekly formulation of risedronate sodium hydrate was approved in 2002 in the United States and now are being approved in more than 80 countries around the world. -
August 20, 2012
August 20, 2012 Prepared: NGO Network for the Elimination of Racial Discrimination (ERD Net) Submitted: The International Movement Against All Forms of Discrimination and Racism – Japan Committee – IMADR-JC To the CERD Secretariat: We are pleased to submit the report concerning the hate speech against minority communities in Japan hoping that this could contribute to the CERD thematic discussion on hate speech of August 30, 2012. The report covers the propaganda of hate speech and dissemination of derogatory messages against some minority communities in Japan, namely Buraku, Zainichi Koreans and migrants. The present report does not cover the other minority communities such as Ryukyu-Okinawans and the Ainu, but we believe that a similar manifestation would be demonstrated against them when they face the challenge of hate speech. When we discuss about the hate speech in Japan, it is nothing but only a problem under no control. The main reasons rest with the absence of criminal code that prohibits and sanctions racist hate speech. Unless a committed hate speech has some connections or implications to other crimes, there is no legal means that forces an immediate halt of such act. Hate speech could constitute an illegal act under the civil law and only when it is aimed at specific individuals. As indicated in several cases contained in this report, perpetrators of hate speech have been arrested, charged and convicted for the crimes of defamation, forgery of private documents, damage to property, and etc. that are not intended to sanction hate speech. Racially motivated acts are only sanctioned as petty crimes under the present law in Japan, thus, conviction of such acts is less effective in terms of prevention of crimes. -
Nagoya / Movies
NAGOYA 2 AENGLISHL EDITIONENWebsite:D www.nic-nagoya.or.jpAR 2021 Phone: 052-581-0100 February 「Nagoya Calendar」は生活情報や名古屋周辺の C イベント等の情報を掲載している英語の月刊情報誌です。 I N S L TE O RN HO ATIONAL SC The Nagoya Calendar is printed on recycled paper that contains post-consumer recycled pulp. Unauthorized reproduction of contents prohibited. Aichi Asahi Site Museum, Kiyosu City Nagoya International Center News & Events Nagoya International Center Information Counter – Phone: 052-581-0100 ★NIC consultations available in person at NIC, by phone or online (via Skype). See the NIC website for details. The Nagoya International Center is a 7-minute walk or a 2-minute ★Information Counter 情報カウンター subway ride from Nagoya Station. Information on daily life and sightseeing in 9 languages (times vary), Japanese Kokusai Center Station, on the Sakura-dori Subway Line, is linked to the & English available Tue. to Sun. 9:00 – 19:00. Phone: 052-581-0100, E-mail: Nagoya International Center at the basement level. [email protected] ★Free Personal Counseling 外国人こころの相談 English-speaking counselor available on Sun. by appointment to provide support to those with difficulties in their lives in Japan. Reservations: Call the NIC 3F Info Counter at 052-581-0100. Portuguese, Spanish, Chinese also available. ★Free Legal Consultations 外国人無料法律相談 Consultations with a certified lawyer available on Sat. 10:00 - 12:30 by reservation only. Please leave your name & phone number on the answering machine at 052-581-6111. A staff member will call you back at a later date to schedule your appointment. ★Gyoseishoshi Consultations 行政書士による相談 Consult a certified administrative procedures legal specialist about procedures related to immigration, setting up a business, etc. -
Mizuho Financial Group, Inc
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2016 OR ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number 001-33098 Kabushiki Kaisha Mizuho Financial Group (Exact name of Registrant as specified in its charter) Mizuho Financial Group, Inc. (Translation of Registrant’s name into English) Japan (Jurisdiction of incorporation or organization) 1-5-5 Otemachi Chiyoda-ku, Tokyo 100-8176 Japan (Address of principal executive offices) Masahiro Kosugi, +81-3-5224-1111, +81-3-5224-1059, address is same as above (Name, Telephone, Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class Name of each exchange on which registered Common Stock, without par value The New York Stock Exchange* American depositary shares, each of which represents two shares of The New York Stock Exchange common stock Securities registered or to be registered pursuant to Section 12(g) of the Act. None (Title of Class) Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None (Title of Class) Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report. -
EA Pharma Filed Marketing Approval Application for AJM300 (Nonproprietary Name: Carotegrast Methyl) Indicated for Treatment of Ulcerative Colitis
May 28, 2021 EA Pharma Co., Ltd. Kissei Pharmaceutical Co., Ltd. (Code 4574, Tokyo Stock Exchange 1st Section) EA Pharma Filed Marketing Approval Application for AJM300 (Nonproprietary Name: Carotegrast Methyl) Indicated for Treatment of Ulcerative Colitis EA Pharma Co., Ltd. (President, Yuji Matsue; Headquarters, Chuo-ku, Tokyo, Japan; “EA Pharma”) and Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa; "Kissei") announced that EA Pharma has filed the marketing approval application in Japan for AJM300 (nonproprietary name: carotegrast methyl), which the two companies have developed for treatment of ulcerative colitis. The application was filed based on the results of Phase III clinical study (AJM300/CT3) and other studies conducted in Japan. Detailed data of AJM300/CT3 will be presented at an upcoming major medical conference this year. AJM300 is an orally available small molecule α4 integrin antagonist that was originated by EA Pharma (formerly known as Ajinomoto Pharmaceuticals Co., Ltd.). EA Pharma and Kissei have jointly developed AJM300 since 2015, aiming to launch the world-first orally available α4 integrin antagonist onto the market. In ulcerative colitis, lymphocytes and other inflammatory cells excessively aggregate and invade into the inflamed site in the colonic mucosa. AJM300 can antagonize both α4β1 and α4β7 integrins expressed on the surface of inflammatory cells and inhibit the cell adhesion mediated by binding to adhesion molecules excessively expressed on the vascular endotherial cells in the colonic mucosa, which suppresses invasion of lymphocytes into the inflamed site to exert anti-inflammation effects. EA Pharma and Kissei strive to quickly provide AJM300 for clinical use to increase treatment options for ulcerative colitis to contribute to QOL of patiens and their families. -
Nagoya Living Guide(PDF)
English This guidebook provides helpful informaiton for daily life to foreign residents living in Nagoya for the first time. Please keep this guide handy and refer to it whenever you need help. Nagoya Living Guide is also available online. Information and Consultations in Foreign Languages Please feel free to contact us if you have Tue Wed Thu Fri Sat Sun a problem or a question about living in English 9:00 - 19:00 Japan. Portugueses ��������� 10:00 - 12:00 Spanish ������� 13:00 - 17:00 10:00 - 12:00 052-581-0100 Chinese ���� 13:00 - 17:00 13:00 - 17:00 Korean ������ 13:00 - 13:00 - 17:00 Nagoya International Center (NIC) Filipino �������� 17:00 13:00 13:00 - - https://www.nic-nagoya.or.jp Vietnamese ���������� 17:00 17:00 13:00 ����������� - See p.3 Nepali 17:00 Nagoya Japanese Language Classroom List A list of Japanese language classrooms in Nagoya City, ������ where you can study Japanese for free or a minimal fee! https://www.nic-nagoya.or.jp/en/living in nagoya/ living information/living_information/2019/09201200.html Emergency Contacts 110(free) 119(free) Theft, crimes, Fires, emergencies traffic accidents, etc. (sudden illness or injury), etc. Information on Hospitals Offering Services in Foreign Languages 050-5810-5884 Aichi Emergency Treatment Information Center English �� ������ Português Español We offer automatic voice and fax services for medical information Search See p.6, 23 p. 3 p. 4 Contents Nagoya International Housing Center (NIC) p. 6 p. 7 p. 8 Hospitals, Insurance, Separation and Collection of Jobs and Pensions Recyclables and Garbage p. 10 p. -
Corporate Governance Report 2021
Corporate Governance Report CORPORATE GOVERNANCE Ajinomoto Co.,Inc. Final Update: June 29, 2021 Ajinomoto Co., Inc. Takaaki Nishii, Representative Executive Officer, President & Chief Executive Officer Contact: Corporate Planning Dept. +81-3-5250-8111 Securities code: 2802 https://www.ajinomoto.com/ The corporate governance of Ajinomoto Co., Inc. (the “Company”) is described below. Ⅰ. Basic policy on corporate governance and capital structure, business attributes and other basic information 1. Basic Policy Maintaining the founding philosophy of improving nutrition of general public by using umami seasonings to make a simple diet tasty, the Ajinomoto Group as an “Solution-Providing Group of Companies for Food and Health Issues” has achieved growth since its establishment in a consistent manner through initiatives to co - create social value and economic value by conducting business. These kinds of initiatives have been named ASV (The Ajinomoto Group Creating Shared Value) and ASV is positioned at the core of our management policy (hereinafter, “ASV Management”). To realize our 2030 vision of bec oming a company that “contributes to greater wellness for people worldwide, unlocking the power of amino acids to resolve the food and health issu es associated with dietary habits and aging,” we will continue to endeavor to strengthen corporate governance by advancing ASV Ma nagement. The Ajinomoto Principle on Corporate Governance is disclosed at the website below. This principle enables stakeholders to eas ily understand the Ajinomoto Group’s continued efforts for strengthening its corporate governance in ASV Management, serv es as a mainstay in cultivating dialogue and coordination, and is resolved by the Board of Directors. https://www.ajinomoto.co.jp/company/en/ir/strategy/corp_gov/main/0/teaserItems1/03/linkList/03/link/principle_E.pdf [Reasons for non-compliance with the principles of the Corporate Governance Code] Ajinomoto Co., Inc. -
Companies Participating Upon the Creation of the Study Group (In the Order of the Japanese Syllabary) Ajinomoto Co., Inc
June 11, 2020 Mizuho Financial Group, Inc. Establishment of and Participation in the ESG Disclosure Study Group Comprised of 19 Companies in the Private Sector Mizuho Financial Group, Inc. (President & CEO: Tatsufumi Sakai) today announced that it will take part in the ESG Disclosure Study Group ( a general incorporation association; “the Study Group”) which is planned to be established in late June 2020. At the time of its creation, the Study Group will consist of 19 private sector companies and will carry out research related to ESG information disclosure with the goal of creating a mechanism to establish harmony between the sustained development of society and the individual efforts of companies to enhance corporate value and growth. Mr. Tetsuo Kitagawa, Professor Emeritus at Aoyama Gakuin University and a specially appointed professor at Tokyo Metropolitan University, will assume the post of Representative Director of the Study Group and concurrently serve as Chairperson to supervise the Study Group’s research. Companies participating upon the creation of the Study Group (in the order of the Japanese syllabary) Ajinomoto Co., Inc. Asset Management One Co., Ltd. EY Japan Kao Corporation KDDI Corporation KPMG Japan Goldman Sachs Asset Management Co Ltd. Goldman Sachs Japan Co., Ltd Seven & i Holdings Co., Ltd. Sompo Holdings, Inc. Takeda Pharmaceutical Company Co., Ltd. Deloitte Touche Tohmatsu LLC Tokyo Electric Power Company Holdings, Incorporated Nippon Life Insurance Company PwC Japan Group Hitachi, Ltd. Mizuho Financial Group, Inc. Sumitomo Mitsui Trust Asset Mitsubishi UFJ Financial Group, Inc. Management Co., Ltd. In recent years, ESG investment, which considers environmental, social and governance factors in investment decisions and appraisals, has accelerated in capital markets, while companies face the challenges of ESG information disclosure and efficient and effective stakeholder engagement, including with institutional investors. -
Ajinomoto Co., Inc. Financial Report 2013 for the Year Ended March 31, 2013 AJINOMOTO CO., INC
Cover (p1) Ajinomoto Co., Inc. Financial Report 2013 For the year ended March 31, 2013 AJINOMOTO CO., INC. FINANCIAL REPORT 2013 Financial Report 2013 Ajinomoto Co., Inc. and Consolidated Subsidiaries >>> For the year ended March 31, 2013 Contents Contents >>> Message from the CEO 3 Financial Section Six-Year Summary of Selected Financial Data 9 Management’s Discussion and Analysis 10 Consolidated Balance Sheets 22 Consolidated Statements of Income 24 Consolidated Statements of Comprehensive Income 25 Consolidated Statement of Changes in Net Assets 26 Consolidated Statements of Cash Flows 28 Notes to Consolidated Financial Statements 29 Report of Independent Auditors 54 Corporate Data Major Subsidiaries and Affiliates 55 Investor Information and Links 57 FORWARD-LOOKING STATEMENTS This financial report contains forward-looking statements regarding the plans, outlook, strategies and results of the Ajinomoto Group. All forward- looking statements are based on judgments derived from the information available to the Group at the time of publication. Certain risks and uncertainties could cause the Group’s actual results to differ materially from any projections presented in this report. These risks and uncertainties include, but are not limited to, the economic circumstances surrounding the Group’s businesses; competitive pressures; related laws and regulations; product development programs; and changes in ex change rates. Note: In this document the Ajinomoto Group is referred to as “the Group”, and Ajinomoto Co., Inc. is referred to as “Ajinomoto Co.” or “the Company”. AJI-NO-MOTO® is the trademark of the Ajinomoto Group’s umami seasoning products. *Geographical area segments are categorized on the basis of geographic proximity and indicated in inverted commas.